Camurus AB/Skr CAMX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Camurus AB
Camurus AB is a biopharmaceutical company headquartered in Lund, Sweden, specializing in the development of innovative pharmaceuticals for the treatment of serious and chronic diseases. The company's core offerings focus on proprietary drug delivery technologies, including FluidCrystal® technology, which enhances the therapeutic benefits and delivery of active ingredients. Camurus concentrates its efforts on areas such as addiction treatment, pain management, and oncology, aiming to improve patient outcomes through advanced formulations. The company operates in several international markets, leveraging strategic partnerships and a focused product pipeline to maintain its position within the biopharmaceutical industry. Its operations are characterized by a strong emphasis on research and development to sustain and expand its portfolio.
- Ticker
- Skr CAMX
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 316
- Headquarters
- Lund, Sweden
- Website
- www.camurus.com
Camurus AB Metrics
BasicAdvanced
kr 40B
59.61
kr 11.31
0.43
-
Price and volume
Market cap
kr 40B
Beta
0.43
52-week high
kr 710.00
52-week low
kr 430.80
Average daily volume
87K
Financial strength
Current ratio
10.005
Quick ratio
9.346
Long term debt to equity
0.019
Total debt to equity
0.023
Interest coverage (TTM)
140.93%
Profitability
EBITDA (TTM)
822.984
Gross margin (TTM)
93.07%
Net profit margin (TTM)
29.92%
Operating margin (TTM)
35.96%
Effective tax rate (TTM)
21.66%
Revenue per employee (TTM)
kr 7,170,000
Management effectiveness
Return on assets (TTM)
10.47%
Return on equity (TTM)
15.86%
Valuation
Price to earnings (TTM)
59.607
Price to revenue (TTM)
17.729
Price to book
8.56
Price to tangible book (TTM)
8.56
Price to free cash flow (TTM)
61.378
Free cash flow yield (TTM)
1.63%
Free cash flow per share (TTM)
10.981
Growth
Revenue change (TTM)
0.01%
Earnings per share change (TTM)
-6.16%
3-year revenue growth (CAGR)
15.59%
10-year revenue growth (CAGR)
34.20%
3-year earnings per share growth (CAGR)
16.80%
10-year earnings per share growth (CAGR)
14.55%
What the Analysts think about Camurus AB
Analyst ratings (Buy, Hold, Sell) for Camurus AB stock.
Analyst projections of the future price of Camurus AB stock.
Bulls say / Bears say
The established franchise is still growing: Q2 product sales rose 13% year on year to SEK 528 million, while Brixadi royalties increased 42% to SEK 127 million. Camurus reiterated 2026 revenue guidance of SEK 2.6–2.9 billion, giving investors a commercial base beyond its pipeline. (Camurus)
Eli Lilly expanded its collaboration with Camurus to include amylin receptor agonists, adding another drug class to the partnership. The agreement offers potential milestone payments and royalties if Lilly’s programmes progress and reach sales. (PR Newswire)
The FDA issued a second Complete Response Letter for CAM2029 in acromegaly over unresolved issues at a third-party manufacturing site, not clinical efficacy or safety. Although the resubmission was accepted, the new US decision date is 18 December 2026, delaying the commercial opportunity and leaving execution risk. (Reuters, PR Newswire)
The start of 2026 showed how uneven performance can be: Q1 revenue fell 5% year on year, product sales fell 12%, and operating profit dropped 30%. Q2 recovered, but the weak first quarter raises the risk that full-year guidance depends on sustained improvement. (Camurus)
The business remains concentrated in a small number of products: Buvidal generated SEK 524 million of Q2 sales against total product sales of SEK 528 million, while Brixadi generated SEK 127 million in royalties. That leaves results exposed to the fortunes of the core franchise and, for US Brixadi sales, its licensing partner. (Camurus, BioStock)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
Camurus AB Financial Performance
Revenues and expenses
Camurus AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Camurus AB
AllUSDEURGBP
Fund name | Fund size | Skr CAMX weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.17% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.17% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.02% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.02% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.